In the current study, we investigated whether Staphylococcus aureus grown from affected skin of atopic dermatitis (AD) patients secreted identifiable toxins that could act as allergens to induce IgE-mediated basophil histamine release. The secreted toxins of S. aureus grown from AD patients were identified by ELISA using antibodies specific for staphylococcal enterotoxin (SE) exfoliative toxin (ET), or toxic shock syndrome toxin (TSST-1). S. aureus isolates from 24 of 42 AD patients secreted identifiable toxins with SEA, SEB, and TSST accounting for 92% of the isolates. 32 of 56 AD sera (57%) tested contained significant levels of IgE primarily to SEA, SEB, and/ or TSST. In contrast, although SEA, SEB, or TSST secreting S. aureus could be recovered from the skin of psoriasis patients, their sera did not contain IgE antitoxins.
Introduction
Atopic dermatitis (AD)' is a chronic pruritic inflammatory skin disorder characterized by the infiltration of T cells and monocyte macrophages into the local skin lesion (1, 2) . Although it is thought that immunologic mechanisms contribute to the pathogenesis of this skin disease, the actual events that result in this common skin condition are poorly understood (3) . Several observations, however, suggest that IgE and/or allergens may play a role: First, the majority ofpatients with AD have a personal or family history ofatopic disease, e.g., asthma or allergic rhinitis. Second, serum IgE levels are elevated in about 80% of patients with AD (4) . In this regard, serum IgE levels have been reported to correlate with extent of skin disease (5) . Third, most patients with AD have positive immediate skin tests and radioallergosorbent tests for IgE to various food and inhalant allergens (6) . Fourth, double-blinded placebocontrolled food challenge studies have demonstrated that food allergies can trigger cutaneous reactions in a subset of children with AD (7) . In the latter studies, serial skin biopsies and sampling ofplasma for histamine release suggested that the inflammatory cell infiltrate associated with food challenges was the result of an allergen-induced IgE-dependent late phase cutaneous reaction (8, 9) . Finally, mite-specific Th2-type lymphocytes have been cloned from skin lesions of AD patients with IgEspecific antibody to dust mites (10, 1 1).
Although clinically relevant food-induced dermatitis has been convincingly demonstrated, it affects only a minority of patients with AD. In this regard, it is of interest that there are numerous reports suggesting that S. aureus contributes to the exacerbation of this skin disease (12) (13) (14) (15) . Leyden and coworkers (12) first demonstrated that S. aureus could be isolated from the affected skin of over 90% of patients with AD. In contrast, the skin of normal subjects harbored this organism in only 5% of their cases, and its localization was mainly in the nose and intertriginous areas. Using quantitative methods, the density of S. aureus on inflamed AD lesions without clinical superinfection can reach up to 107 colony-forming units/cm2 (13) . Clinically, it is also well known that not only patients with impetiginized AD but also patients without superinfection show a better clinical response to combined treatment with antistaphylococcal antibiotics and topical corticosteroids than to corticosteroids alone ( 16).
Patients with the hyperimmunoglobulin E (HIE) and recurrent infection syndrome produce high levels of IgE antibody directed against the cell wall of S. aureus (17) (18) (19) . Although recurrent superficial staphylococcal pustulosis can be a significant problem in AD, the invasive S. aureus infections, e.g., recurrent pneumonias, seen in HIE syndrome, do not occur (20) . S. aureus is known to secrete toxins with potent immunogenic properties (21) . Since such toxins could be absorbed from the surface of inflamed AD skin, the current study was carried out to determine whether S. aureus isolated from AD skin secretes identifiable toxins that could act as allergens to induce histamine release from the basophils and mast cells of AD patients armed with IgE to staphylococcal toxins. Methods
Patients. 56 patients with moderate to severe AD (greater than 20% skin involvement) and elevated serum IgE (serum IgE; median = 9847, range 880-40,682 IU/ml) were studied. Sera were available for analysis of IgE antitoxin from all 56 patients. 42 ofthese 56 patients were available for culture of their skin, all of whom yielded S. aureus isolates for characterization of exotoxin production (see below). Their diagnosis was based on the criteria of Hanifin and Rajka (1). All patients had a history of requiring oral antibiotics on at least one occasion for superficial skin infections, e.g., pustulosis or impetigo. None ofthese patients, however, had a history of deep-seated S. aureus skin infections. Four control groups were studied: first, 15 (17) (18) (19) (20) was based on a history ofrecurrent sinusitis, pneumonia, deep-seated skin and pulmonary abscesses predominantly caused by S. aureus, chronic eczematoid dermatitis, and marked elevation of serum IgE (median IgE = 22,000, range: 5500-34,000 IU/ml) with an increased proportion of IgE directed to S. aureus strain Wood 46 (protein A-deficient). Informed consent was obtained from all subjects before performing these studies.
Analysis of toxins secreted by S. aureus grown from AD skin. In these experiments, S. aureus isolated from AD lesional skin were grown overnight at 370C in brain heart infusion broth (Difco Laboratories, Detroit, MI). 0.1 ml of the overnight growth was then applied and spread over the surface ofa brain heart infusion agar plate overlaid with a 6-8,000 mol wt cut offdialysis membrane (Spectra/Por, Los Angeles, CA) as previously described (22) . The membrane over agar plates was then incubated overnight at 370C. The next day the bacteria were harvested by resuspending them in 0.5 ml of 0.01 M Na2HPO4, 0.9% NaCl, pH = 7.4. The bacteria suspension was centrifuged at 10,000 rpm for 10 min, and the supernatant was collected for identification of toxin secretion.
The ELISA for detection of staphylococcal toxin was carried out as previously described (23). 96 well flat-bottomed, polystyrene microtiter plates (Nunc, Roskilde, Denmark) were coated with 0.1 ml of staphylococcal toxin-specific polyclonal rabbit IgG (Toxin Technology, Sarasota, FL) diluted to a 10 gg/ml concentration in 0.05 M Na2CO3, pH = 9.5. After that, the plates were covered and incubated at 370C for 12-14 h. The plates were then washed three times with PBS (PBS-0 0.1 M NA2HPO4, 0.9%, NaCl, pH = 7.4) with 0.05% Tween 20 (PBS-Tween).
Before exotoxin assay, the S. aureus culture supernatants were diluted 1:4 in PBS-Tween. Normal rabbit serum containing no antibodies to staphylococcal exotoxins (Toxin Technology) was added to a concentration of 1% and the mixture was incubated for 30 min at 250C. 100 ,g of these mixtures was then added to the IgG antitoxin coated wells and shaken 100 rpm for 2 h at 370C. The plates were then washed three times with PBS-Tween. 100 Ml of toxin-specific polyclonal rabbit IgG conjugated to horseradish peroxidase (Toxin Technology) were then added to each well. The plates were shaken at 100 rpm for 1 h at 370C. and washed 10 times with PBS-Tween. 100 Ml of substrate solution consisting of 3% 2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS; Sigma Immunochemicals, St. Louis, MO 22,23) and 0.001% H202 in 0.05 M citrate buffer, pH = 4.0 was added to each well. After 30 min, the wells were read at 410 nm. In these assays, serial dilutions of purified toxin solutions (range: 0.6-10 ng/ml) are used as standards. The sensitivity ofthese assays was approximately 1 ng/ml.
Assay of IgE anti-S. aureus exotoxins. As previously described (24) , flat-bottomed, polystyrene microtiter plate (Nunc) wells were filled with 100 Al ofa I0-Ag/ml solution of highly purified staphylococcal exotoxin (SE) (either SEA, SEB, SEC, SED, ET, or TSST-1; Toxin Technology) in 0.05 M Na2CO3 buffer, pH = 9.5. The plates were covered and shaken overnight at 100 rpm at 370C. The following day the plates were washed three times with PBS-Tween. Serum to be tested was diluted 1:4 and 1:8 in PBS-Tween, then 100 Ml of each dilution were placed into a precoated well. The plates were then washed three times with PBS-Tween. 100 Ml ofa 1:1000 dilution ofgoat anti-human IgE (Sigma Chemical Co.) were placed in the wells. The plates were incubated at 370C for 1 h while being shaken at 100 rpm. The plates were then washed 10 times with PBS-Tween. 100 Ml of a I-Ag/ml solution ofp-nitrophenyl phosphate (Sigma Chemical Co.) in 9.7% diethanolamine buffer, pH = 9.8 was placed in each well. The plates were incubated at 250C for 1 h, then read at 410 nm. In all experiments, background was < 0.05 and was subtracted from the values obtained with test samples. Specificity ofthe assay was demonstrated by the loss of IgE binding in the presence of soluble toxin added to test samples.
Preparation ofperipheral-blood basophils. Venous blood was collected in sterile plastic syringes containing EDTA (pH 7.2) at a final concentration of 25 mM. The syringes were inverted several times for proper mixing, and then the anticoagulated samples were added to detergent-free polycarbonate tubes containing 6% Dextran 70 (Pharmacia Fine Chemicals, Uppsala, Sweden). The erythrocytes were sedimented at room temperature for 90 min, and the leukocyte-containing plasma was removed. After centrifugation at 300 g for 12 min at 4°C, the cell pellet was washed three times in cold Hepes-buffered saline (0.01 M, pH 7.4) containing 0.3 mg HSA/ml. The final cell pellet was resuspended and adjusted to 10-15 X 106 cells/ml in Hepes-buffered saline containing albumin, 2 mM calcium, and 1 mM magnesium (Hepes-ACM) for use in the histamine release assay.
Leukocyte histamine-release assay. Duplicate 50-MAl aliquots of the leukocyte suspension(=-1.5-2 X 104basophils) were incubated in polystyrene tubes containing 50 Ml ofprewarmed Hepes-ACM for 45 min at 37°C to determine the rate of spontaneous release of histamine by basophils. Similar duplicate samples were heated at 100°C for 10 min to measure the total histamine content. To determine the rate of histamine release by basophils that was induced by staphylococcal exotoxins, either 1 ng/ml, 10 ng/ml, 100 ng/ml, or 1 Mg/ml of the respective toxins was added to 50 Ml of the leukocyte preparation (1.5-2 X 104 basophils), and the cell suspension was incubated for 45 min at 37°C. The cell suspensions were spun down, the supernatants were removed, and the histamine content was determined utilizing a sensitive radioenzymic assay, modified from the method of Verburg et al. (25) This assay uses purified histamine methyltransferase and gives results that were highly reproducible within the range of 30 pg to 10 ng/ml. The release ofhistamine, either spontaneously or as induced by staphylococcal toxin, was recorded as a percentage ofthe total leukocyte histamine content. The basophils were counted by means of toluidine blue (26) staining.
Lactic acid stripping ofbasophil IgE. Surface-bound IgE was dissociated from the basophils with the use ofthe lactic acid elution method ofPruzansky et al. (27) . The leukocytes were washed once in buffer and once in normal saline, resuspended in 5 ml of 0.01 M lactic acid (pH 3.9) containing 140 mM sodium chloride and 5 mM potassium chloride, and incubated for 3.5 min at 23°C. Cells were then diluted in 30 ml of Pipes buffer containing 25 mM Pipes, 1 10 mM sodium chloride, Table I , S. aureus isolates from 24 ofthe 42 AD patients secreted identifiable toxins. Furthermore, SEA, SEB, and TSST-1 accounted for 22 of the 24 (92%) identifiable toxins. S. aureus was isolated from 9 of the 16 patients with psoriasis. These staphylococcal organisms were also found primarily to secrete either SEA, SEB, or TSST-1 (Table I) .
Presence of IgE antitoxin in AD and HIE syndrome. In these experiments, we determined whether serum from 56 AD patients contained IgE antibodies directed against S. aureus exotoxins. 32 of the 56 AD (57%) sera tested had increased IgE binding to either SEA, SEB, SEC, SED, ET, or TSST-1 (Fig. 1) . These AD sera were, however, predominantly positive for IgE to SEA, SEB, and TSST1. Of note, 22 of the AD sera reacted with only one of the six toxins tested, nine reacted with two of these toxins and only one of these sera reacted with all three toxins. Furthermore, sera from 21 ofthe 24 patients in Table I against at least three toxins (Fig. 1) . Furthermore, unlike the AD sera, five ofthe seven HIE patient sera tested contained IgE against SEC, SED, and ET. Since patients with AD contain high levels of total serum IgE, we were concerned with the possibility that the high frequency ofIgE against staphylococcal toxins was due to nonspecific IgE binding. This is unlikely for several reasons: first, the ELISA assay using staphylococcal toxins as the capture antigen was unable to detect binding of myeloma IgE (PS) at levels of IgE up to 200,000 IU/ml) (data not shown). Second, binding of patient serum IgE to plastic wells coated with the various staphylococcal toxins was completely inhibited by preincubation of positive sera with the corresponding staphylococcal toxin at a concentration of 1 ,g/ml. Finally, there was no correlation between IgE antitoxin level and total IgE level. In this regard, the total IgE level of sera from patients who had IgE antitoxin (mean serum IgE = 7152±1741 IU/ml) was similar to the total IgE level of sera from patients without IgE antitoxin (mean serum IgE = 5258± 1797 IU/ml; P = 0.4).
S. aureus toxin-induced histamine release from AD basophils. To study the potential functional role of IgE antistaphylococcal toxins in AD, we assessed the capacity of staphylococcal toxins to induce histamine release from freshly isolated basophils of AD patients and normal controls. In these experiments, basophils were incubated either with medium to determine spontaneous histamine release or with SEA, SEB, and TSST-1. The data shown in Tables II and III were derived from experiments in which the toxins were used at 100 ng/ml. Similar data, however, was obtained when these toxins were used at 10 ng/ml and 1 ig/ml. Net basophil histamine release (spontaneous histamine release subtracted from toxin-induced histamine release) > 5% was considered significant.
As depicted in Table II , no control subject's basophils released > 2% histamine to any staphylococcal toxin: mean± 1 SD ofSEA = 0.30%±0.53%; SEB = 0.70%±0.72%; and TSST-I = 0. 14%±0.22%. Similarly, basophils from AD patients lacking identifiable toxin-specific IgE (group 1 in Table III) failed to release any significant histamine: mean± 1 SD of SEA = 1.00%±0.93%; SEB = 1.38%±1.30%; and TSST-l = 1.51%± 1.40%. In contrast, patients in group 2 of Table III , who had serum IgE antibodies against staphylococcal toxins, released significant amounts (5-59%) of total basophil histamine in response to at least one staphylococcal toxin: six patients to SEA, six to SEB, and four patients to TSST-1; mean± 1 SD of SEA = 7.50%±7.27%; SEB = 12.10%±10.02%; and TSST-1 = 9.58±17.76%. As a group, AD patients in group 2 of Table III released significantly more basophil histamine to all staphylococcal toxins tested compared with AD group 1 (P < 0.01). Basophil histamine released from individual donors, however, only occurred when the respective donor had circulating IgE against the relevant staphylococcal toxin. Furthermore, there was a significant correlation between the presence of serum IgE antitoxin and positive toxin-induced basophil histamine release (P = 0.52 by McNemar test for association between the two assays).
To demonstrate that the histamine release by AD basophils in response to staphylococcal toxins occurred through an IgEdependent mechanism, basophils from an unrelated atopic donor were stripped ofsurface-bound IgE and passively sensitized with various AD sera. Table IV shows that stripped basophils obtained from an atopic donor sensitized with myeloma IgE did not respond to SEA, SEB, or TSST1. Sensitization of stripped basophils with AD sera lacking IgE antitoxin (ADl and AD2 in Table III ) did not result in the release of histamine to any of the toxins tested. However, when these stripped human basophils were sensitized with three AD sera (3-5 in Table  III) containing IgE to toxin, increased levels of histamine release was observed, but only when exposed to the relevant toxin but not to other toxins. More important, we have found that removal ofIgE from AD sera depletes the activity that mediates toxin-induced basophil histamine release (data not shown). Furthermore, toxin-induced histamine release in a dose-dependent manner from stripped human basophils that were sensitized with sera containing IgE antitoxin. As shown in Table V , maximum histamine release was observed at toxin concentrations of 10 and 100 ng/ml. We have found that removal of IgE from AD sera depletes the activity that mediates toxin-induced basophil histamine release. In the experiments shown in Table VI , we removed IgE from sera ofpatients with IgE anti-TSST by affinity chromatography over an anti-IgE column with a decrease in serum IgE level for patient M.E. from 30,000 to 269 IU/ml, and from 12,855 to 234 IU/ml for patient W.W. As shown in Table VI , before removal of IgE, sensitization of stripped basophils with sera from patient M.E. and W.W. resulted in significant levels of TSST-induced histamine release. However, sensitization of stripped basophils with IgE-depleted sera resulted in no TSSTinduced histamine release. Taken together, these data indicate that toxin-induced histamine release from stripped basophils sensitized with AD sera containing IgE antitoxin involves the recognition of IgE on the basophil surface.
Discussion
It is well established that S. aureus can be an important trigger for the exacerbation of AD (10-14). The current study documents that S. aureus isolated from the skin ofmore than halfof AD patients secrete identifiable toxins, primarily SEA, SEB, and TSST. Recent studies demonstrating that these staphylococcal toxins can act as superantigens (21) (30, 31) . Since patients with AD are colonized with S. aureus, the continuous release ofexotoxins into the skin may promote the chronic inflammation found in AD.
The specificity of our current observations for AD is supported by the lack of IgE antitoxin in normal controls and patients with respiratory allergy. More (15) (16) (17) (18) . In contrast, patients with AD do not produce IgE antibodies against the cell wall of S. aureus (18, 33) . The divergent IgE response between these two diseases may be due to the fact that HIE syndrome is associated with deep-seated S. aureus infections. In contrast, AD is associated with superficial S. aureus skin infections and colonization. In the latter situation, only the secreted exotoxins would be expected to penetrate the skin. These data strongly suggest that patients with AD are exposed to S. aureus exotoxins in a clinically and immunologically significant manner and that these exotoxins may participate in several mechanisms to trigger AD. Interestingly, there also appears to be a difference between these two diseases in their spectrum ofIgE responses directed to staphylococcal toxins. The majority of AD patients produce IgE against either SEA, SEB, or TSST. In contrast, patients with HIE syndrome produce IgE against multiple staphylococcal toxins including SEC, SED, and ET. Although the basis of these observations are not clear, the differences in IgE responses between HIE syndrome and AD may reflect the increased frequency of different S. aureus infections in HIE syndrome as well the more invasive nature of these infections (34, 35) .
In summary, our current data indicate that the majority of patients with AD and all patients with HIE syndrome mount an IgE response to staphylococcal exotoxins that can be grown from their skin. In particular, these toxins may exacerbate AD and perpetuate tissue inflammation by inducing degranulation of mast cells, basophils, Langerhans cells, and/or other Fcereceptor bearing cells armed with the relevant IgE antitoxin. These data may also explain the clinical observation that many flares of eczema correlate with high colonization counts of S. aureus on the skin and that the skin rash frequently resolves when S. aureus is eradicated or drastically reduced following antibiotic therapy. New strategies for the treatment of this increasingly common skin disease may include ones that interfere with the production of toxin by S. aureus.
